Standard BioTools and Next Gen Diagnostics announce the execution of a long-term agreement aimed at revolutionizing the automation of sample preparation for pathogen whole genome sequencing. Under the exclusive agreement, Standard BioTools will manufacture the NGD-100, a version of its microfluidics-based Biomark X9 System customized for NGD and optimized for automated pathogen WGS library preparation.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LAB:
- Standard BioTools to Participate in Upcoming Investor Conferences
- Standard BioTools Announces Conference Call and Webcast for Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
- Standard BioTools and Navignostics Announce Collaboration Agreement to Advance Imaging Capabilities in Personalized Medicine
- Standard BioTools, Navignostics announce collaboration agreement
- LAB Earnings Report this Week: Is It a Buy, Ahead of Earnings?
